How are you managing care delivery during the COVID-19 pandemic?

Published on April 8, 2020 in Treatment

Download Transcript Download Audio

Daniel A. Pollyea, MD
Clinical Director of Leukemia Services
Associate Professor of Medicine
Division of Hematology
University of Colorado
Denver, Colorado

I've recently been asked several questions regarding the current state of the medical system in general and how that may impact patients with AML and it all relates to of course the COVID-19 outbreak. So the first question here is “how are you managing care delivery during the COVID-19 pandemic?”

So I think this is a very, very fluid situation. I'm recording this end of March of 2020 and things are changing very rapidly. There's also a lot of regional differences. At our Center though at this particular moment, we are doing as many things as we can. We're trying to delay or cancel routine visits, or some of the more standard check-in type things for a couple months down the road for people who can wait. Our program in general is trying to delay other things that may not be essential right now, like planned autologous stem cell transplants for patients with other types of diseases, but newly diagnosed AML patients is not something that can wait and we're business as usual there. So from a care delivery perspective for those urgent situations, we are doing our best to move forward as we always do during these very difficult times.

Last modified: April 7, 2020